Gonadotropin-Releasing Hormone Agonist-Induced Pituitary Apoplexy in Treatment of Prostate Cancer: Case Report and Review of Literature

2007 ◽  
Vol 13 (6) ◽  
pp. 642-646 ◽  
Author(s):  
Kathleen Hands ◽  
Andrea Alvarez ◽  
Jan Bruder
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Pituitary Apoplexy ◽  
Gonadotropin Releasing Hormone ◽  
Cancer Case ◽  
Prostate Cancer Case ◽  
Review Of Literature ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist

scholarly journals Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment

2020 ◽  
Vol 2020 ◽  
Author(s):  
Mariana Barbosa ◽  
Sílvia Paredes ◽  
Maria João Machado ◽  
Rui Almeida ◽  
Olinda Marques
Keyword(s):  
Prostate Cancer ◽  
Gnrh Agonist ◽  
Advanced Prostate Cancer ◽  
Healthcare Professionals ◽  
Pituitary Apoplexy ◽  
Gonadotropin Releasing Hormone ◽  
List Type ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Life Threatening

Summary Gonadotropin-releasing hormone (GnRH) agonists, currently used in the treatment of advanced prostate cancer, have been described as a rare cause of pituitary apoplexy, a potentially life-threatening clinical condition. We report the case of a 69-year-old man with a known pituitary macroadenoma who was diagnosed with prostate cancer and started treatment with GnRH agonist leuprorelin (other hormones were not tested before treatment). Few minutes after drug administration, the patient presented with acute-onset severe headache, followed by left eye ptosis, diplopia and vomiting. Pituitary MRI revealed tumor enlargement and T1-hyperintense signal, compatible with recent bleeding sellar content. Laboratory endocrine workup was significant for low total testosterone. The patient was managed conservatively with high-dose steroids, and symptoms significantly improved. This case describes a rare phenomenon, pituitary apoplexy induced by GnRH agonist. We review the literature regarding this condition: the pathophysiological mechanism involved is not clearly established and several hypotheses have been proposed. Although uncommon, healthcare professionals and patients should be aware of this complication and recognize the signs, preventing a delay in diagnosis and treatment. Learning points: Pituitary apoplexy (PA) is a potentially life-threatening complication that can be caused by gonadotropin-releasing hormone agonist (GnRHa) administration for the treatment of advanced prostate cancer. This complication is rare but should be taken into account when using GnRHa, particularly in the setting of a known pre-existing pituitary adenoma. PA presents with classic clinical signs and symptoms that should be promptly recognized. Patients should be instructed to seek medical care if suspicious symptoms occur. Healthcare professionals should be aware of this complication, enabling its early recognition, adequate treatment and favorable outcome.

scholarly journals Brucellosis mimicking prostate cancer: Case report and review of the literature

2017 ◽  
Author(s):  
Lütfi Canat ◽  
Akif Erbin ◽  
Hasan Tahsin Gözdaş ◽  
Hasan Anıl Atalay
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Cancer Case ◽  
Prostate Cancer Case ◽  
Review Of The Literature

3 Single shot stereotactic body radiotherapy for localized prostate cancer: Case report

2018 ◽  
Vol 56 ◽  
pp. 2 ◽  
Author(s):  
N. Koutsouvelis ◽  
G. Dipasquale ◽  
A. Dubouloz ◽  
M. Jaccard ◽  
R. Miralbell ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Stereotactic Body Radiotherapy ◽  
Localized Prostate Cancer ◽  
Cancer Case ◽  
Single Shot ◽  
Prostate Cancer Case

scholarly journals Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a)

1996 ◽  
Vol 42 (8) ◽  
pp. 1176-1181 ◽  
Author(s):  
L Denti ◽  
G Pasolini ◽  
P Cortellini ◽  
S Ferretti ◽  
L Sanfelici ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cluster Analysis ◽  
Gonadal Hormones ◽  
Gonadotropin Releasing Hormone ◽  
Cross Sectional ◽  
Releasing Hormone ◽  
Lipoprotein A ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Androgen Suppression ◽  
Clear Relation

Abstract No clear relation between lipoprotein(a) [Lp(a)] and endogenous gonadal hormones has been demonstrated. In this study, we compared the effects on Lp(a) of pharmacological castration in 50 patients with prostate cancer who were undergoing therapy with a gonadotropin-releasing hormone agonist (goserelin), with effects on 58 age-matched controls. We also studied 16 untreated patients under baseline conditions and after 3 months of therapy with goserelin alone or combined with an antiandrogen (flutamide). Neither cross-sectional nor prospective studies showed any significant effects of therapy on Lp(a). However, cluster analysis identified a subgroup of patients showing slight but significant increases in Lp(a) concentrations, as well as greater declines of testosterone and estradiol, suggesting that androgen, like estrogen, can exert some slight, though not easily detectable, influence on Lp(a).

Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer

Metabolism ◽  
1990 ◽  
Vol 39 (12) ◽  
pp. 1314-1319 ◽  
Author(s):  
John A. Tayek ◽  
David Heber ◽  
Lauri O. Byerley ◽  
Barbara Steiner ◽  
Jacob Rajfer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gonadotropin Releasing Hormone ◽  
Metabolic Effects ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist
Sign in / Sign up

Export Citation Format

Share Document